Parkinson's Disease - 164 citations found - 98/05/27 - 30 days - PubMed

 Spillantini MG, et al.
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's
disease and dementia with Lewy bodies.
Proc Natl Acad Sci U S A. 1998 May 26; 95(11): 6469-6473.
PMID: 9600990.

 Wakabayashi K, et al.
Apolipoprotein E epsilon4 allele and progression of cortical Lewy body
pathology in Parkinson's disease.
Acta Neuropathol (Berl). 1998 May; 95(5): 450-454.
PMID: 9600590; UI: 98261217.

 Good PF, et al.
Protein nitration in Parkinson's disease.
J Neuropathol Exp Neurol. 1998 Apr; 57(4): 338-342.
PMID: 9600227; UI: 98260854.

 Irizarry MC, et al.
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's
disease and cortical Lewy body disease contain alpha-synuclein
immunoreactivity.
J Neuropathol Exp Neurol. 1998 Apr; 57(4): 334-337.
PMID: 9600226; UI: 98260853.

 Hansen LA, et al.
Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's
disease and dementia.
J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 653-656.
PMID: 9598683; UI: 98258630.

 Colzi A, et al.
Continuous subcutaneous waking day apomorphine in the long term treatment of
levodopa induced interdose dyskinesias in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 May; 64(5): 573-576.
PMID: 9598668; UI: 98258615.

 Liu EH, et al.
Persistent perioperative laryngospasm in a patient with Parkinson's disease.
Can J Anaesth. 1998 May; 45(5 Pt 1): 495. No abstract available.
PMID: 9598268; UI: 98260630.

 Uitti RJ.
Medical treatment of essential tremor and Parkinson's disease.
Geriatrics. 1998 May; 53(5): 46-48.
PMID: 9597979; UI: 98260270.

 Uitti RJ.
Tremor: how to determine if the patient has Parkinson's disease.
Geriatrics. 1998 May; 53(5): 30-36.
PMID: 9597978; UI: 98260269.

 Quinn N, et al.           
Functional neurosurgery for Parkinson's disease. Has come a long way, though
much remains experimental.
BMJ. 1998 Apr 25; 316(7140): 1259-1260. No abstract available.
PMID: 9554893; UI: 98223565.

 Davidson WS, et al.           
Stabilization of alpha-synuclein secondary structure upon binding to synthetic
membranes.
J Biol Chem. 1998 Apr 17; 273(16): 9443-9449.
PMID: 9545270; UI: 98211967.

 Cadet JL, et al.
Free radicals and the pathobiology of brain dopamine systems.
Neurochem Int. 1998 Feb; 32(2): 117-131. Review.
PMID: 9542724; UI: 98203852.

 Factor SA, et al.           
'Sleep benefit' in Parkinson's disease.
Neurology. 1998 May; 50(5): 1514-1515. No abstract available.
PMID: 9596032; UI: 98255471.

 Checkoway H, et al.           
A genetic polymorphism of MAO-B modifies the association of cigarette smoking
and Parkinson's disease.
Neurology. 1998 May; 50(5): 1458-1461.
PMID: 9596006; UI: 98255445.

 Factor SA, et al.           
Acute delirium after withdrawal of amantadine in Parkinson's disease.
Neurology. 1998 May; 50(5): 1456-1458.
PMID: 9596005; UI: 98255444.

 Gorell JM, et al.           
The risk of Parkinson's disease with exposure to pesticides, farming, well
water, and rural living.
Neurology. 1998 May; 50(5): 1346-1350.
PMID: 9595985; UI: 98255424.

 Hogl BE, et al.           
A clinical, pharmacologic, and polysomnographic study of sleep benefit in
Parkinson's disease.
Neurology. 1998 May; 50(5): 1332-1339.
PMID: 9595983; UI: 98255422.

 Growdon JH, et al.           
Levodopa improves motor function without impairing cognition in mild non-
demented Parkinson's disease patients. Parkinson Study Group.
Neurology. 1998 May; 50(5): 1327-1331.
PMID: 9595982; UI: 98255421.

 Verhagen Metman L, et al.           
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's
disease.
Neurology. 1998 May; 50(5): 1323-1326.
PMID: 9595981; UI: 98255420.

 Goetz CG.           
New lessons from old drugs: amantadine and Parkinson's disease.
Neurology. 1998 May; 50(5): 1211-1212. No abstract available.
PMID: 9595964; UI: 98255403.

 Greene SM, et al.           
Symptom study in context: effects of marital quality on signs of Parkinson's
disease during patient-spouse interaction.
Psychiatry. 1998; 61(1): 35-45.
PMID: 9595594; UI: 98257950.

 Castro ME, et al.           
5-HT1B receptor binding in degenerative movement disorders.
Brain Res. 1998 Apr 20; 790(1-2): 323-328.
PMID: 9593971.

 Schapira AHV.           
Human complex I defects in neurodegenerative diseases.
Biochim Biophys Acta. 1998 May 6; 1364(2): 261-270.
PMID: 9593927.

 Walker DG, et al.           
Expression of the proto-oncogene Ret, a component of the GDNF receptor
complex, persists in human substantia nigra neurons in Parkinson's disease.
Brain Res. 1998 May 11; 792(2): 207-217.
PMID: 9593897.

 Gomez-Vargas M, et al.           
Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and
inhibits lipid peroxidation in different regions of the rat brain.
Brain Res. 1998 Apr 20; 790(1-2): 202-208.
PMID: 9593894.

 Van Muiswinkel FL, et al.           
Sustained pharmacological inhibition of nitric oxide synthase does not affect
the survival of intrastriatal rat fetal mesencephalic transplants.
Brain Res. 1998 May 4; 792(1): 48-58.
PMID: 9593818.

 Fischman AJ, et al.           
Rapid detection of Parkinson's disease by SPECT with altropane: a selective
ligand for dopamine transporters.
Synapse. 1998 Jun; 29(2): 128-141.
PMID: 9593103; UI: 98253935.

 Madras BK, et al.           
Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human
dopamine transporter in postmortem normal and Parkinson's diseased brain.
Synapse. 1998 Jun; 29(2): 116-127.
PMID: 9593102; UI: 98253934.

 Baldi I, et al.           
[No title available].
Rev Epidemiol Sante Publique. 1998 Mar; 46(2): 134-142. French.
PMID: 9592856; UI: 98255214.

 Hubble JP, et al.           
Gene-toxin interaction as a putative risk factor for Parkinson's disease with
dementia.
Neuroepidemiology. 1998; 17(2): 96-104.
PMID: 9592786; UI: 98255144.

 Ubeda JV.           
Null hypothesis of husband-wife concordance of Parkinson's disease in 1,000
married couples over age 50 in Spain.
Neuroepidemiology. 1998; 17(2): 90-95.
PMID: 9592785; UI: 98255143.

 Mandel RJ, et al.           
Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated
Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in
a Rat Model of Parkinson's Disease.
J Neurosci. 1998 Jun 1; 18(11): 4271-4284.
PMID: 9592104.

 Kotake Y, et al.           
Deprenyl decreases an endogenous parkinsonism-inducing compound,
1-benzyl-1,2,3,4-tetra-hydro-isoquinoline in mice: in vivo and in vitro
studies.
Brain Res. 1998 Mar 23; 787(2): 341-343.
PMID: 9518683; UI: 98186768.

 Baas H, et al.           
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing
off" phenomenon and levodopa requirements in fluctuating parkinsonian
patients.
Neurology. 1998 May; 50(5 Suppl 5): S46-S53.
PMID: 9591522; UI: 98252196.

 Waters CH, et al.           
Tolcapone in stable Parkinson's disease: efficacy and safety of long-term
treatment. Tolcapone Stable Study Group.
Neurology. 1998 May; 50(5 Suppl 5): S39-S45.
PMID: 9591521; UI: 98252195.

 Jorga KM.           
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of
early studies in volunteers.
Neurology. 1998 May; 50(5 Suppl 5): S31-S38.
PMID: 9591520; UI: 98252194.

 Goetz CG.           
Influence of COMT inhibition on levodopa pharmacology and therapy.
Neurology. 1998 May; 50(5 Suppl 5): S26-S30.
PMID: 9591519; UI: 98252193.

 Chase TN.           
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Neurology. 1998 May; 50(5 Suppl 5): S17-S25.
PMID: 9591518; UI: 98252192.

 Goetz CG.           
Highlights of the North American and European experiences.
Neurology. 1998 May; 50(5 Suppl 5): S15-S16.
PMID: 9591517; UI: 98252191.

 Kurth MC, et al.           
COMT inhibition: a new treatment strategy for Parkinson's disease.
Neurology. 1998 May; 50(5 Suppl 5): S3-S14.
PMID: 9591516; UI: 98252190.

 Fahn S.           
Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
Neurology. 1998 May; 50(5 Suppl 5): S1-S2. No abstract available.
PMID: 9591515; UI: 98252189.

 Lindner MD, et al.           
Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing
cell line in rodent and primate models of Parkinson's disease.
Cell Transplant. 1998 Mar; 7(2): 165-174.
PMID: 9588598; UI: 98248012.

 Othberg AI, et al.           
Trophic effect of porcine sertoli cells on rat and human ventral mesencephalic
cells and HNT neurons in vitro.
Cell Transplant. 1998 Mar; 7(2): 157-164.
PMID: 9588597; UI: 98248011.

 Bakay RA, et al.           
Immunological responses to injury and grafting in the central nervous system
of nonhuman primates.
Cell Transplant. 1998 Mar; 7(2): 109-120.
PMID: 9588593; UI: 98248007.

 Vidal N, et al.           
Morphological and functional evidence for enhanced growth and potassium-evoked
dopamine release in striatal grafts innervated with a patchy growth pattern.
An in oculo nigrostriatal cograft study.
Cell Transplant. 1998 Mar; 7(2): 97-108.
PMID: 9588592; UI: 98248006.

 Blanco L, et al.           
[No title available].
Rev Neurol. 1998 Mar; 26(151): 361-365. Spanish.
PMID: 9585942; UI: 98247034.

 Fox SH, et al.           
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona
reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Exp Neurol. 1998 May; 151(1): 35-49.
PMID: 9582253; UI: 98250832.

 Mercuri NB, et al.           
Modification of levodopa responses by deprenyl (selegiline): an electro-
physiological and behavioral study in the rat relevant to Parkinson's disease.
Ann Neurol. 1998 May; 43(5): 613-617.
PMID: 9585355; UI: 98244754.

 Murer MG, et al.           
Chronic levodopa is not toxic for remaining dopamine neurons, but instead
promotes their recovery, in rats with moderate nigrostriatal lesions.
Ann Neurol. 1998 May; 43(5): 561-575.
PMID: 9585350; UI: 98244749.

 Uhl GR.           
Hypothesis: the role of dopaminergic transporters in selective vulnerability
of cells in Parkinson's disease.
Ann Neurol. 1998 May; 43(5): 555-560. Review. No abstract available.
PMID: 9585349; UI: 98244748.

 Fahn S.           
Welcome news about levodopa, but uncertainty remains.
Ann Neurol. 1998 May; 43(5): 551-554. No abstract available.
PMID: 9585348; UI: 98244747.

 Zawada WM, et al.           
Somatic cell cloned transgenic bovine neurons for transplantation in
parkinsonian rats.
Nat Med. 1998 May; 4(5): 569-574.
PMID: 9585230; UI: 98244629.

 Lloyd GK, et al.           
The potential of subtype-selective neuronal nicotinic acetylcholine receptor
agonists as therapeutic agents.
Life Sci. 1998; 62(17-18): 1601-1606.
PMID: 9585143; UI: 98244542.

 Pacchetti C, et al.           
Active music therapy and Parkinson's disease: methods.
Funct Neurol. 1998 Jan; 13(1): 57-67.
PMID: 9584875; UI: 98244266.

 Nutt JG.           
New pharmacological and surgical therapies for Parkinson's disease.
West J Med. 1998 Apr; 168(4): 267-268. No abstract available.
PMID: 9584671; UI: 98245650.

 Ben-Shlomo Y, et al.           
Investigation by Parkinson's Disease Research Group of United Kingdom into
excess mortality seen with combined levodopa and selegiline treatment in
patients with early, mild Parkinson's disease: further results of randomised
trial and confidential inquiry.
BMJ. 1998 Apr 18; 316(7139): 1191-1196.
PMID: 9583926; UI: 98245965.

 Blaszczyk JW.           
Motor deficiency in Parkinson's disease.
Acta Neurobiol Exp (Warsz). 1998; 58(1): 79-93.
PMID: 9583191; UI: 98244026.

 Davey GP, et al.
Energy Thresholds in Brain Mitochondria. Potential involvement in
neurodegeneration.
J Biol Chem. 1998 May 22; 273(21): 12753-12757.
PMID: 9582300.

 Abrams KR.           
Monitoring randomised controlled trials. Parkinson's disease trial illustrates
the dangers of stopping early.
BMJ. 1998 Apr 18; 316(7139): 1183-1184. No abstract available.
PMID: 9552993; UI: 98221041.

 Breteler MM.           
Selegiline, or the problem of early termination of clinical trials. The
clinical questions are not well answered, and probably never will be.
BMJ. 1998 Apr 18; 316(7139): 1182-1183. No abstract available.
PMID: 9552992; UI: 98221040.

 Vaughan JR, et al.           
Sequencing of the alpha-synuclein gene in a large series of cases of familial
Parkinson's disease fails to reveal any further mutations. The European
Consortium on Genetic Susceptibility in Parkinson's Disease (GSPD).
Hum Mol Genet. 1998 Apr; 7(4): 751-753.
PMID: 9499430; UI: 98167862.

 Castano A, et al.           
Lipopolysaccharide intranigral injection induces inflammatory reaction and
damage in nigrostriatal dopaminergic system.
J Neurochem. 1998 Apr; 70(4): 1584-1592.
PMID: 9580157; UI: 98181720.

 Gage FH.           
Cell therapy.
Nature. 1998 Apr 30; 392(6679 Suppl): 18-24. Review.
PMID: 9579857; UI: 98239460.

 Merello M, et al.           
Changes in the motor response to acute L-dopa challenge after unilateral
microelectrode-guided posteroventral pallidotomy.
Clin Neuropharmacol. 1998 Mar; 21(2): 135-138.
PMID: 9579303; UI: 98240466.

 Nacasch N, et al.           
Clozapine for the treatment of agitated-depressed patients with cognitive
impairment: a report of three cases.
Clin Neuropharmacol. 1998 Mar; 21(2): 132-134.
PMID: 9579302; UI: 98240465.

 Lyons KE, et al.           
Gender differences in Parkinson's disease.
Clin Neuropharmacol. 1998 Mar; 21(2): 118-121.
PMID: 9579298; UI: 98240461.

 Bedard MA, et al.           
Attentional deficits in Parkinson's disease: partial reversibility with
naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist.
Clin Neuropharmacol. 1998 Mar; 21(2): 108-117.
PMID: 9579297; UI: 98240460.

 Brooks DJ, et al.           
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole
dopaminergic therapy in Parkinson's disease.
Clin Neuropharmacol. 1998 Mar; 21(2): 101-107.
PMID: 9579296; UI: 98240459.

 Sternic N, et al.           
The therapeutic effect of moclobemide, a reversible selective monoamine
oxidase a inhibitor, in Parkinson's disease.
Clin Neuropharmacol. 1998 Mar; 21(2): 93-96.
PMID: 9579294; UI: 98240457.

 Baas H, et al.           
Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian
patients with end-of-dose motor fluctuations.
Clin Neuropharmacol. 1998 Mar; 21(2): 86-92.
PMID: 9579293; UI: 98240456.

 Kuno S, et al.           
Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-
treated cynomolgus monkeys.
Clin Neuropharmacol. 1998 Jan; 21(1): 35-40.
PMID: 9579283; UI: 98240446.

 Brefel C, et al.           
Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.
Br J Clin Pharmacol. 1998 Apr; 45(4): 412-415.
PMID: 9578193; UI: 98237304.

 Seitz G, et al.           
Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene
expression in the human neuroblastoma cell line SK-N-SH.
Neurosci Lett. 1998 Mar 6; 244(1): 33-36.
PMID: 9578138; UI: 98237249.

 Praamstra P, et al.           
Evidence for lateral premotor and parietal overactivity in Parkinson's disease
during sequential and bimanual movements. A PET study.
Brain. 1998 Apr; 121( Pt 4): 769-772. No abstract available.
PMID: 9577401; UI: 98238262.

 Majsak MJ, et al.           
The reaching movements of patients with Parkinson's disease under self-
determined maximal speed and visually cued conditions.
Brain. 1998 Apr; 121( Pt 4): 755-766.
PMID: 9577399; UI: 98238260.

 Johnson KA, et al.           
Bimanual co-ordination in Parkinson's disease.
Brain. 1998 Apr; 121( Pt 4): 743-753.
PMID: 9577398; UI: 98238259.

 Alberts JL, et al.           
The co-ordination and phasing of a bilateral prehension task. The influence of
Parkinson's disease.
Brain. 1998 Apr; 121( Pt 4): 725-742.
PMID: 9577397; UI: 98238258.

 Scott R, et al.           
Neuropsychological, neurological and functional outcome following pallidotomy
for Parkinson's disease. A consecutive series of eight simultaneous bilateral
and twelve unilateral procedures.
Brain. 1998 Apr; 121( Pt 4): 659-675.
PMID: 9577392; UI: 98238253.

 Inzelberg R, et al.           
Auditory hallucinations in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 Apr; 64(4): 533-535.
PMID: 9576549; UI: 98236086.

 Hayes AE, et al.           
Toward a functional analysis of the basal ganglia.
J Cogn Neurosci. 1998 Mar; 10(2): 178-198.
PMID: 9555106; UI: 98223722.

 Zawada WM, et al.           
Growth factors improve immediate survival of embryonic dopamine neurons after
transplantation into rats.
Brain Res. 1998 Mar 9; 786(1-2): 96-103.
PMID: 9554968; UI: 98223483.

 Masalha R, et al.           
Selective dopamine neurotoxicity by an industrial chemical: an environmental
cause of Parkinson's disease? 1. [Brain research 774 (1997) 260-264].
Brain Res. 1998 Mar 2; 785(2): 359. No abstract available.
PMID: 9518694; UI: 98186720.

 de la Monte SM, et al.           
P53- and CD95-associated apoptosis in neurodegenerative diseases.
Lab Invest. 1998 Apr; 78(4): 401-411.
PMID: 9564885; UI: 98224556.

 Kelly MA, et al.           
Locomotor activity in D2 dopamine receptor-deficient mice is determined by
gene dosage, genetic background, and developmental adaptations.
J Neurosci. 1998 May 1; 18(9): 3470-3479.
PMID: 9547254; UI: 98213724.

 Azizi SA, et al.           
Engraftment and migration of human bone marrow stromal cells implanted in the
brains of albino rats--similarities to astrocyte grafts.
Proc Natl Acad Sci U S A. 1998 Mar 31; 95(7): 3908-3913.
PMID: 9520466; UI: 98188303.

 Almeida A, et al.           
A rapid method for the isolation of metabolically active mitochondria from rat
neurons and astrocytes in primary culture.
Brain Res Brain Res Protoc. 1998 Mar; 2(3): 209-214.
PMID: 9507134; UI: 98176023.

continued in part two....

janet paterson aka calendar control supervisor
51/10 - sinemet/selegiline/prozac - [log in to unmask]
quotations: http://newww.com/cgi-bin/do_cal?c:newvoice
pwp event calendar: http://newww.com/cgi-bin/do_cal?c:pwpc